Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by shareswapperon Apr 09, 2020 1:12pm

402 Views

Post# 30894784

Alexion Knows Bertilimumab Is a Winner

That's why they snagged the rights from Immune in the first place. There are many potential indications for this drug and Alexion will not want ICO having the Occular aspects. They need to buy ICO out to secure 100% and on top of that they know they will get a winner in Amp B, which is a low cost "no brainer". Watch for M&A here, pretty sure it's in the works.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?